哮喘联盟

   摘要
   目的：本研究评价奥玛珠单抗治疗非特应性哮喘的疗效。
   方法：通过对严重哮喘多中心注册研究数据进行分析，对29名奥玛珠单抗治疗的重度非特应性哮喘患者和266名奥玛珠单抗治疗的重度过敏性哮喘患者进行评价和比较。通过严重哮喘发作、肺功能、全球治疗效果评价(GETE)量表和哮喘控制测试（ACT）来评价治疗的有效性。
   结果：奥玛珠单抗能显著改善非特应性哮喘患者的临床状态，GETE评分从1.6±1.1增加至4个月时的2.8±0.8(p=0.0215)、1年时的2.9±0.9(p=0.0093)和2年时的3.4±0.6；ACT评分从13.0±5.5增加至4个月时的17.5±5.4(p=0.0236)、1年时的17.9±4.8 (p=0.0136)和2年时的20.6±3.9(p=0.0024)。第一秒用力呼气体积（FEV1）从61.0±19.4%改善至4个月时的65.1±17.2、1年时的64.1±24.7和2年时的67.3±23.0，但随访检测结果与初始结果无显著差异(p分别为0.52, 0.91和0.45)。哮喘发作从3.1±3.5次下降至1年时的1.9±2.8 (p=0.1709)和2年时的1.8±4.4 (p=0.2344)。上述结果与特应性哮喘患者类似。
   结论：抗IgE治疗能有效改善非特应性严重哮喘的症状。
 

（苏楠 审校）
J Asthma. 2013 Jan 28. [Epub ahead of print]
 

Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry.
 
de Llano LP, Vennera MD, Alvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA,Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; on behalf of the Spanish Registry.

Source
Department of Pneumology, Hospital Xeral-Calde , Rua Doutor Ochoa, Lugo , Spain.

Abstract 
AIM： To evaluate the effectiveness of omalizumab in non-atopic asthma.
METHODS：Using data from a multicenter registry of severe asthma, we evaluated and compared the clinical outcome of 29 omalizumab-treated severe non-atopic asthmatics with 266 omalizumab-treated severe allergic asthmatics. Effectiveness was assessed by considering severe exacerbations, pulmonary function, the Global Evaluation of Treatment Effectiveness (GETE) scale, and Asthma Control Test (ACT).
RESULTS：Omalizumab demonstrated significant improvement in the clinical status of non-atopic asthmatics as measured by GETE, which rose from 1.6 ± 1.1 to 2.8 ± 0.8 at 4 months (p = .0215) to 2.9 ± 0.9 at 1 year (p = .0093) and to 3.4 ± 0.6 at 2 years (p = .0078), and by the ACT, which increased from 13.0 ± 5.5 to 17.5 ± 5.4 at 4 months (p = .0236) to 17.9 ± 4.8 at 1 year (p = .0136) and to 20.6 ± 3.9 at 2 years (p = .0024). Forced expiratory volume in 1 second (FEV(1)) improved from 61.0 ± 19.4% to 65.1 ± 17.2 at 4 months to 64.1 ± 24.7 at 1 year and to 67.3 ± 23.0 at 2 years, but without significant differences between initial and follow-up measurements (p = .52, .91, and .45, respectively) and exacerbations decreased from 3.1 ± 3.5 to 1.9 ± 2.8 at 1 year (p = .1709) to 1.8 ± 4.4 at 2 years (p = .2344). The results were not significantly different from those obtained in atopic asthmatics.
CONCLUSION：Anti-IgE therapy can be effective in non-atopic severe asthma.

J Asthma. 2013 Jan 28. [Epub ahead of print]